Toward novel vaccines and therapies based on negative-strand RNA viruses

V. Von Messling, Roberto Cattaneo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The study of negative-strand RNA viruses has suggested new strategies to produce more attenuated viruses. Reverse genetics has allowed the implementation of the strategies, and new or improved monovalent vaccines are being developed. In addition, recombinant viruses expressing foreign proteins or epitopes have been produced with the aim of developing multivalent vaccines capable of stimulating humoral and cellular immune responses against more than one pathogen. Finally, recombinant viruses that selectively enter cells expressing tumor markers or the HIV envelope protein have been engineered and shown to lyse target cells. Preclinical and clinical trials of improved and multivalent vaccines and therapeutic (oncolytic) viruses are ongoing.

Original languageEnglish (US)
Pages (from-to)281-312
Number of pages32
JournalCurrent Topics in Microbiology and Immunology
Volume283
StatePublished - 2004

Fingerprint

Active Immunotherapy
RNA Viruses
Vaccines
Viruses
Oncolytic Viruses
Human Immunodeficiency Virus Proteins
Reverse Genetics
Tumor Biomarkers
Humoral Immunity
Cellular Immunity
Epitopes
Clinical Trials
Proteins
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Microbiology

Cite this

Toward novel vaccines and therapies based on negative-strand RNA viruses. / Von Messling, V.; Cattaneo, Roberto.

In: Current Topics in Microbiology and Immunology, Vol. 283, 2004, p. 281-312.

Research output: Contribution to journalArticle

@article{a81b197f81cf4890864f7940426d239b,
title = "Toward novel vaccines and therapies based on negative-strand RNA viruses",
abstract = "The study of negative-strand RNA viruses has suggested new strategies to produce more attenuated viruses. Reverse genetics has allowed the implementation of the strategies, and new or improved monovalent vaccines are being developed. In addition, recombinant viruses expressing foreign proteins or epitopes have been produced with the aim of developing multivalent vaccines capable of stimulating humoral and cellular immune responses against more than one pathogen. Finally, recombinant viruses that selectively enter cells expressing tumor markers or the HIV envelope protein have been engineered and shown to lyse target cells. Preclinical and clinical trials of improved and multivalent vaccines and therapeutic (oncolytic) viruses are ongoing.",
author = "{Von Messling}, V. and Roberto Cattaneo",
year = "2004",
language = "English (US)",
volume = "283",
pages = "281--312",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Toward novel vaccines and therapies based on negative-strand RNA viruses

AU - Von Messling, V.

AU - Cattaneo, Roberto

PY - 2004

Y1 - 2004

N2 - The study of negative-strand RNA viruses has suggested new strategies to produce more attenuated viruses. Reverse genetics has allowed the implementation of the strategies, and new or improved monovalent vaccines are being developed. In addition, recombinant viruses expressing foreign proteins or epitopes have been produced with the aim of developing multivalent vaccines capable of stimulating humoral and cellular immune responses against more than one pathogen. Finally, recombinant viruses that selectively enter cells expressing tumor markers or the HIV envelope protein have been engineered and shown to lyse target cells. Preclinical and clinical trials of improved and multivalent vaccines and therapeutic (oncolytic) viruses are ongoing.

AB - The study of negative-strand RNA viruses has suggested new strategies to produce more attenuated viruses. Reverse genetics has allowed the implementation of the strategies, and new or improved monovalent vaccines are being developed. In addition, recombinant viruses expressing foreign proteins or epitopes have been produced with the aim of developing multivalent vaccines capable of stimulating humoral and cellular immune responses against more than one pathogen. Finally, recombinant viruses that selectively enter cells expressing tumor markers or the HIV envelope protein have been engineered and shown to lyse target cells. Preclinical and clinical trials of improved and multivalent vaccines and therapeutic (oncolytic) viruses are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=2442704214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442704214&partnerID=8YFLogxK

M3 - Article

C2 - 15298173

AN - SCOPUS:2442704214

VL - 283

SP - 281

EP - 312

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

ER -